Premier Medical Group of the Hudson Valley, PC

Poughkeepsie, New York 12603

1 studies enrolling now · 36 studies all time

What they study most

Bladder Cancer, Breast Cancer, Cancer of the Prostate, Chronic Idiopathic Constipation, Colitis, Ulcerative, Colorectal Cancer, Crohn Disease, Crohn's Disease, Esophageal Cancer, Hematuria - Cause Not Known, Hepatitis C, Hormone Sensitive Prostate Cancer

Studies at this site

• Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine. — Recruiting now
• A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Running, not enrolling
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Running, not enrolling
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer — Running, not enrolling
• A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency — Completed
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year — Completed
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB) — Completed
• A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) — Completed
• A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency — Completed
• Autologous Muscle Derived Cells for Female Urinary Sphincter Repair — Completed
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors — Completed
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis — Completed
• A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults — Completed
• Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease — Stopped early
• A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis — Completed
• Long-Term Safety Of PF-00547659 In Ulcerative Colitis — Completed
• A Study To Monitor Long-Term Treatment With PF-00547659 — Completed
• Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease — Stopped early
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• The Plecanatide Chronic Idiopathic Constipation (CIC) Study — Completed
• Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer — Completed
• Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer — Completed
• Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women — Completed
• Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer — Stopped early
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling
• A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease — Completed
• The Safety And Efficacy Of Maintenance Therapy With CP-690,550 — Completed
• Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis — Stopped early
• UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects — Completed
• Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy — Completed
• Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV — Completed
• Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder — Completed